MA43551A - Protéines immunomodulatrices à variants du ligand icos et leurs utilisations - Google Patents

Protéines immunomodulatrices à variants du ligand icos et leurs utilisations

Info

Publication number
MA43551A
MA43551A MA043551A MA43551A MA43551A MA 43551 A MA43551 A MA 43551A MA 043551 A MA043551 A MA 043551A MA 43551 A MA43551 A MA 43551A MA 43551 A MA43551 A MA 43551A
Authority
MA
Morocco
Prior art keywords
variant
immunomodulator
proteins
icos
ligand
Prior art date
Application number
MA043551A
Other languages
English (en)
French (fr)
Inventor
Michael Kornacker
Ryan Swanson
Original Assignee
Alpine Immune Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpine Immune Sciences Inc filed Critical Alpine Immune Sciences Inc
Publication of MA43551A publication Critical patent/MA43551A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA043551A 2016-04-15 2017-04-14 Protéines immunomodulatrices à variants du ligand icos et leurs utilisations MA43551A (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662323608P 2016-04-15 2016-04-15
US201662394745P 2016-09-14 2016-09-14
US201662410842P 2016-10-20 2016-10-20
US201762472568P 2017-03-16 2017-03-16
US201762475162P 2017-03-22 2017-03-22

Publications (1)

Publication Number Publication Date
MA43551A true MA43551A (fr) 2018-11-07

Family

ID=60042799

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043551A MA43551A (fr) 2016-04-15 2017-04-14 Protéines immunomodulatrices à variants du ligand icos et leurs utilisations

Country Status (14)

Country Link
US (3) US10882914B2 (enExample)
EP (1) EP3442999A2 (enExample)
JP (3) JP7058609B2 (enExample)
KR (4) KR102536850B1 (enExample)
CN (1) CN110088126A (enExample)
AU (2) AU2017250358B2 (enExample)
BR (1) BR112018070934A2 (enExample)
CA (1) CA3019199A1 (enExample)
IL (2) IL262365B2 (enExample)
MA (1) MA43551A (enExample)
MX (2) MX2018012472A (enExample)
NZ (3) NZ787246A (enExample)
SG (1) SG11201808457PA (enExample)
WO (1) WO2017181148A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE049791T2 (hu) 2015-02-19 2020-10-28 Compugen Ltd PVRIG elleni antitestek és alkalmazási eljárások
KR20240046641A (ko) 2015-04-17 2024-04-09 알파인 이뮨 사이언시즈, 인코포레이티드 조율가능한 친화성을 갖는 면역조절 단백질
MX2018005517A (es) 2015-11-02 2018-11-09 Five Prime Therapeutics Inc Polipeptidos del dominio extracelular de cd80 y su uso en el tratamiento del cancer.
KR102764225B1 (ko) 2016-04-15 2025-02-07 알파인 이뮨 사이언시즈, 인코포레이티드 Cd80 변이체 면역조절 단백질 및 그의 용도
MA43551A (fr) 2016-04-15 2018-11-07 Alpine Immune Sciences Inc Protéines immunomodulatrices à variants du ligand icos et leurs utilisations
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
CA3041039A1 (en) * 2016-10-19 2018-04-26 Cellectis Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
EP3872180A1 (en) * 2016-10-20 2021-09-01 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
KR20190141146A (ko) 2017-03-16 2019-12-23 알파인 이뮨 사이언시즈, 인코포레이티드 Pd-l2 변이체 면역조절 단백질 및 그의 용도
IL268781B2 (en) 2017-03-16 2025-09-01 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
WO2018201014A1 (en) 2017-04-28 2018-11-01 Five Prime Therapeutics, Inc. Methods of treatment with cd80 extracellular domain polypeptides
EP3634466A4 (en) * 2017-06-06 2021-03-24 Relinia, Inc. MONOCATENARY TNF RECEPTOR 2 AGONIST FUSION PROTEINS
CN121021670A (zh) 2017-10-10 2025-11-28 高山免疫科学股份有限公司 Ctla-4变体免疫调节蛋白和其用途
US20200283500A1 (en) * 2017-10-18 2020-09-10 Alpine Immune Sciences, Inc. Variant icos ligand immunomodulatory proteins and related compositions and methods
EP3735417A1 (en) 2018-01-03 2020-11-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
CN111527108A (zh) 2018-03-27 2020-08-11 西雅图免疫公司 制导和导航控制蛋白的制造和使用方法
WO2019226922A1 (en) * 2018-05-24 2019-11-28 Rush University Medical Center Icosl for use as a renal therapeutic
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
CN112638944A (zh) 2018-08-23 2021-04-09 西进公司 抗tigit抗体
CN113366023A (zh) * 2019-01-24 2021-09-07 弗罗里达中央大学研究基金会 用于刺激自然杀伤细胞的组合物和方法
EP3930733A4 (en) * 2019-03-01 2023-03-15 Achelois Biopharma, Inc. METHODS OF MODULATION OF CD160 FUNCTION IN THE ANTIGEN-SPECIFIC IMMUNE CELL AND USES THEREOF
EP3934666A1 (en) * 2019-03-08 2022-01-12 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
EP3955953A1 (en) * 2019-04-17 2022-02-23 Alpine Immune Sciences, Inc. Methods and uses of variant icos ligand (icosl) fusion proteins
EP3999079A4 (en) * 2019-07-19 2024-04-03 Memorial Sloan Kettering Cancer Center Fusion polypeptide for immunotherapy
US20230303984A1 (en) * 2020-02-25 2023-09-28 Momenta Pharmaceuticals, Inc. Enzymes for Sialylation of Glycans
EP4146683A1 (en) 2020-05-08 2023-03-15 Alpine Immune Sciences, Inc. April and baff inhibitory immunomodulatory proteins and methods of use thereof
CN118843469A (zh) * 2022-01-28 2024-10-25 北卡罗来纳大学教堂山分校 自然杀伤t细胞及其使用方法
EP4486787A1 (en) * 2022-03-03 2025-01-08 Board of Regents, The University of Texas System Anti-cd19 and anti-cd79b chimeric antigen receptors and methods of use thereof
EP4506358A1 (en) * 2022-05-03 2025-02-12 Korea University Research and Business Foundation Icos-l variant with enhanced binding affinity for icos
TW202519543A (zh) 2023-09-29 2025-05-16 美商崔克斯生物公司 TNF-α變體融合分子

Family Cites Families (185)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5443964A (en) 1987-08-10 1995-08-22 Duke University Poxvirus insertion/expression vector
US6218525B1 (en) 1988-02-25 2001-04-17 The General Hospital Corporation Nucleic acid encoding CD28
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5580756A (en) 1990-03-26 1996-12-03 Bristol-Myers Squibb Co. B7Ig fusion protein
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
DK0584266T3 (da) 1991-05-06 2003-12-29 Us Gov Health & Human Serv Rekombinant virus udtrykkende carcinoembryonalt antigen og fremgangsmåder til anvendelse heraf
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
WO1994011026A2 (en) 1992-11-13 1994-05-26 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
US5773253A (en) 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
US6130316A (en) 1993-07-26 2000-10-10 Dana Farber Cancer Institute Fusion proteins of novel CTLA4/CD28 ligands and uses therefore
US6218510B1 (en) 1994-03-02 2001-04-17 Brigham & Woman's Hospital B7-1 and B7-2 polypeptides
US20020159979A1 (en) 1994-06-06 2002-10-31 Children's Hospital, Inc. Adeno-associated virus materials and methods
WO1996009380A1 (en) 1994-09-23 1996-03-28 The University Of British Columbia Method of enhancing expression of mhc class i molecules bearing endogenous peptides
DE69519521T2 (de) 1994-10-03 2001-06-28 The Government Of The United States Of America, As Represented By The Secretary National Institute Of Health Zusammensetzung enthaltend ein antigen exprimierendes rekombinantes virus und ein immunstimulierendes molekül exprimierendes rekombinantes virus
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
US5767071A (en) 1995-06-07 1998-06-16 Ixsys Incorporated Sevenmer cyclic peptide inhibitors of diseases involving αv β3
US5780426A (en) 1995-06-07 1998-07-14 Ixsys, Incorporated Fivemer cyclic peptide inhibitors of diseases involving αv β3
FR2735789B1 (fr) 1995-06-23 1997-07-25 Centre Nat Rech Scient Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant
JPH11514853A (ja) 1995-09-08 1999-12-21 ジエンザイム コーポレイション 遺伝子治療のための改良されたａａｖベクター
US7001765B2 (en) 1996-03-06 2006-02-21 Medigene Ag Adeno-associated virus vector for boosting immunogenicity of cells
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
US6730512B2 (en) 1997-04-09 2004-05-04 Amdl, Inc. Combination immunogene therapy
AU751659B2 (en) 1997-05-02 2002-08-22 Genentech Inc. A method for making multispecific antibodies having heteromultimeric and common components
US5891432A (en) 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
US6635472B1 (en) 1997-08-15 2003-10-21 Rubicon Laboratory, Inc. Retrovirus and viral vectors
CA2304168A1 (en) 1997-09-19 1999-04-01 The Trustees Of The University Of Pennsylvania Methods and cell line useful for production of recombinant adeno-associated viruses
GB9801930D0 (en) 1998-01-29 1998-03-25 Univ London Mutant herpes simplex viruses and uses thereof
ES2292236T3 (es) 1998-04-02 2008-03-01 Genentech, Inc. Variantes de anticuerpos y sus fragmentos.
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US20040063094A1 (en) 1998-05-20 2004-04-01 Biovex Limited Mutant herpes simplex viruses and uses thereof
US6436392B1 (en) 1998-05-20 2002-08-20 University Of Iowa Research Foundation Adeno-associated virus vectors
GB2337755B (en) 1998-05-29 2003-10-29 Secr Defence Virus vaccine
NZ509974A (en) 1998-08-07 2003-10-31 Univ Washington Immunological herpes simplex virus antigens and methods for use thereof
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2364997A3 (en) 1999-01-15 2012-07-04 Genentech, Inc. Polypeptide variants with altered effector function
US8624010B1 (en) 1999-02-03 2014-01-07 Steven K. Yoshinaga Nucleic acids encoding B7RP1
GB9904582D0 (en) 1999-02-26 1999-04-21 Nycomed Imaging As Process
US6428968B1 (en) 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
DE19933288A1 (de) 1999-07-15 2001-01-18 Medigene Ag Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung
US6365619B1 (en) 1999-07-22 2002-04-02 Novartis Ag Treatment of arteriosclerosis
JP4827353B2 (ja) 1999-08-09 2011-11-30 ターゲティッド ジェネティクス コーポレイション 鎖内塩基対を形成するような配列の設計による、組換えウイルスベクターからの一本鎖の異種ヌクレオチド配列の発現の増大
WO2001021796A2 (en) 1999-09-21 2001-03-29 Genetics Institute, Inc. Gl50 molecules and uses therefor
US7241447B1 (en) 1999-10-07 2007-07-10 University Of Iowa Research Foundation Adeno-associated virus vectors and uses thereof
US7329728B1 (en) 1999-10-25 2008-02-12 The Scripps Research Institute Ligand activated transcriptional regulator proteins
EP1242116A2 (en) 1999-12-22 2002-09-25 Onyx Pharmaceuticals, Inc. Herpes simplex virus-1 glycoprotein c mutants for treating unwanted hyperproliferative cell growth
BR0107736A (pt) 2000-01-21 2002-11-19 Biovex Ltd Uso de uma cepa de vìrus não laboratorial, métodos para determinar se um gene tem um efeito sobre um fenótipo associado com um distúrbio dos sistemas nervosos periférico e central ou sobre uma célula dos sistemas nervosos periférico e central, para determinar se um gene codifica um antìgeno associado com uma infecção patogênica ou câncer, para determinar a adequabilidade de uma cepa de vìrus não laboratorial para modificação em uma cepa modificada, para determinar se um gene aumenta os efeitos anti-tumorais de um vìrus e para produzir uma cepa de vìrus não laboratorial oncolìtica, modificada, cepa de vìrus não laboratorial, uso de um gene, cepa hsv1 js1, composição farmacêutica, e, métodos para tratar um tumor em um indivìduo, para suprir um gene a um indivìduo e para tratar ou impedir um distúrbio do sistemas nervosos periférico e central
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
US7094875B2 (en) 2000-06-23 2006-08-22 Maxygen, Inc. Co-stimulatory polypeptides
US7183376B2 (en) 2000-06-23 2007-02-27 Maxygen, Inc. Variant B7 co-stimulatory molecules
CA2413857C (en) 2000-06-28 2010-04-27 Genetics Institute, Llc. Pd-l2 molecules: pd-1 ligands and uses therefor
US7011972B2 (en) 2000-07-18 2006-03-14 The Scripps Research Institute Fusion polypeptide comprising two ligand binding domains
US6635750B1 (en) 2000-07-20 2003-10-21 Millennium Pharmaceuticals, Inc. B7-H2 nucleic acids, members of the B7 family
US6653103B2 (en) 2001-03-30 2003-11-25 Wisconsin Alumni Research Foundation Inhibition of nucleocytoplasmic transport by vesicular stomatitis virus M protein-like polypeptides
CA2442648C (en) 2001-05-11 2012-10-16 Pro-Virus, Inc. Oncolytic virus therapy
EP1406653A4 (en) 2001-06-29 2005-05-04 Univ Leland Stanford Junior T CELL REGULATION GENES AND METHOD OF USE THEREOF
CA2452517A1 (en) 2001-07-11 2003-01-23 University Of Miami Recombinant vsv for the treatment of tumor cells
CN1304559C (zh) 2001-10-09 2007-03-14 杭州康科生物技术有限公司 表达热休克蛋白的溶瘤微生物及其应用
CA2468258C (en) 2001-11-30 2011-10-11 Jeffrey Schlom Peptide agonists of prostate-specific antigen, and uses therefor
US7235631B2 (en) * 2002-02-07 2007-06-26 Mayo Foundation For Medical Education And Research ICOS mutants
CA2479763A1 (en) 2002-03-27 2003-10-09 Baylor College Of Medicine Potent oncolytic herpes simplex virus for cancer therapy
US8535672B2 (en) 2002-04-04 2013-09-17 Yissum Research Development Of The Hebrew University Of Jerusalem Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between CD28 and the superantigen and uses thereof
US20030225260A1 (en) 2002-04-30 2003-12-04 Snyder Richard O. Production of recombinant AAV virions
EP1539230A4 (en) 2002-06-21 2007-10-31 Wellstat Biologics Corp ADMINISTRATION OF THERAPEUTIC VIRUSES
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
EP1549756A4 (en) 2002-09-09 2006-05-10 Univ Tennessee Res Foundation RECOMBINANT MUTANTS OF RHABDOVIRUS AND METHOD OF USE THEREOF
MXPA05003395A (es) 2002-10-03 2005-06-22 Wyeth Corp Polipeptidos de virus de papiloma humano y composiciones inmunogenas.
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
PL212899B1 (pl) 2002-12-16 2012-12-31 Genentech Inc Humanizowane przeciwcialo, kompozycja zawierajaca to przeciwcialo, wyrób fabryczny, przeciwcialo lub jego fragment do zastosowania w sposobie indukowania apoptozy, izolowany kwas nukleinowy, wektor ekspresji, komórka gospodarza, sposób wytwarzania przeciwciala lub jego fragmentu, plynny preparat i zastosowanie przeciwciala do wytwarzania leku
ATE417115T1 (de) 2003-03-27 2008-12-15 Ottawa Health Research Inst Mutante vesicular stomatitis viren und deren verwendungen
US7731974B2 (en) 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
AU2004289953B2 (en) 2003-06-18 2008-09-25 Genelux Corporation Modified recombinant vaccina viruses and other microorganisms, uses thereof
EP2298926A1 (en) 2003-09-30 2011-03-23 The Trustees of The University of Pennsylvania Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
EP1694852B1 (en) 2003-11-17 2010-10-13 Crusade Laboratories Limited Mutant herpes simplex virus and use thereof in the treatment of squamous cell cancer
US7897146B2 (en) 2003-11-17 2011-03-01 Crusade Laboratories Limited Treatment using herpes simplex virus
GB0326798D0 (en) 2003-11-17 2003-12-24 Crusade Lab Ltd Methods for generating mutant virus
BRPI0417107A (pt) 2003-12-19 2007-02-06 Genentech Inc fragmento de anticorpo, métodos de preparação do fragmento de anticorpo, ácido nucléico isolado, composições, célula hospedeira e métodos de fabricação e de geração de fragmento de anticorpo
EP2067789A1 (en) 2004-04-13 2009-06-10 F. Hoffmann-La Roche Ag Anti-P selectin antibodies
WO2005116224A2 (en) 2004-05-18 2005-12-08 Children's Memorial Hospital Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system
US7427396B2 (en) 2004-06-03 2008-09-23 Genzyme Corporation AAV vectors for gene delivery to the lung
WO2006002394A2 (en) 2004-06-24 2006-01-05 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
SI2471813T1 (sl) 2004-07-15 2015-03-31 Xencor, Inc. Optimirane Fc variante
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
JP4958555B2 (ja) 2004-09-22 2012-06-20 協和発酵キリン株式会社 安定化されたヒトＩｇＧ４抗体
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
US20090208924A1 (en) 2004-12-01 2009-08-20 Bayer Schering Pharma Aktiengesellschaft Generation of Replication Competent Viruses for Therapeutic Use
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
CA2611056C (en) 2005-06-01 2016-06-28 California Institute Of Technology Method of targeted gene delivery using viral vectors
EP1909849B1 (en) 2005-06-23 2013-08-07 The University Of Houston Use of mutant herpes simplex virus-2 for cancer therapy
BRPI0614040B8 (pt) 2005-07-18 2021-05-25 Amgen Inc anticorpo isolado que se liga especificamente a b7rp1, polipeptídeo, composição farmacêutica, vetor de expressão, célula hospedeira, linhagem celular isolada e métodos para a detecção de b7rp1 em uma amostra biológica e de produção de um anticorpo ou polipeptídeo
US7943374B2 (en) 2005-08-21 2011-05-17 Markus Hildinger Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
GB0522476D0 (en) 2005-11-03 2005-12-14 Biovex Ltd Oncolytic herpes virus vectors
JP5539718B2 (ja) 2006-07-21 2014-07-02 カリフォルニア インスティテュート オブ テクノロジー 樹状細胞の免疫付与用の、標的特異的な遺伝子輸送
EP2415783B1 (en) 2006-10-16 2016-12-14 Genelux Corporation Modified vaccinia virus strains for use in a diagnostic and therapeutic method
AU2007331672A1 (en) 2006-12-15 2008-06-19 Ablynx N.V. Amino acid sequences that modulate the interaction between cells of the immune system
US20100178684A1 (en) 2006-12-21 2010-07-15 Woo Savio L C Transgenic oncolytic viruses and uses thereof
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
EP2114420B1 (en) 2007-02-16 2016-01-27 Virttu Biologics Limited Herpes simplex viruses and methods of viral replication
CA2690627C (en) 2007-06-15 2014-12-02 Genelux Corporation Microorganisms for imaging and/or treatment of tumors
CN101784564B (zh) 2007-07-13 2014-07-02 约翰霍普金斯大学 B7-dc变体
EP2173368A1 (en) 2007-07-18 2010-04-14 Genelux Corporation Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy
TWI464262B (zh) 2007-09-26 2014-12-11 中外製藥股份有限公司 抗體固定區的變異
EP2212696B1 (en) 2007-10-25 2013-12-04 Genelux Corporation Systems and methods for viral therapy
JP2011505795A (ja) 2007-11-27 2011-03-03 ヴィヴェンティア バイオテクノロジーズ インコーポレーティッド バリアントｎｆｋｂｉｂの癌関連エピトープに対する抗体およびその使用
ES2664988T3 (es) 2007-12-11 2018-04-24 The University Of North Carolina At Chapel Hill Vectores retrovirales modificados del tracto de polipurinas
CA2713872A1 (en) 2008-02-21 2009-08-27 Burnham Institute For Medical Research Methods and compositions related to peptides and proteins with c-terminal elements
US8313896B2 (en) 2008-04-04 2012-11-20 The General Hospital Corporation Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer
EP2300023A2 (en) 2008-05-16 2011-03-30 Genelux Corporation Microorganisms for preventing and treating neoplasms accompanying cellular therapy
WO2009148488A2 (en) 2008-05-29 2009-12-10 The General Hospital Corporation Use of oncolytic herpes viruses for killing cancer stem cells
EP2662383A1 (en) 2008-08-25 2013-11-13 Amplimmune, Inc. PD-I antagonists and methods for treating infectious disease
EP2398466B1 (en) 2008-11-24 2021-02-17 Massachusetts Institute of Technology Methods and compositions for localized nanoparticle delivery to a tumor
US8481297B2 (en) 2009-01-08 2013-07-09 Yale University Compositions and methods of use of an oncolytic vesicular stomatitis virus
US20150359909A1 (en) 2009-07-16 2015-12-17 University College Cork-National University Of Ireland, Cork Orally administered bacteria as vehicles for systemic delivery of agents
EP2283810A1 (en) 2009-07-16 2011-02-16 University College Cork-National University of Ireland, Cork Orally administered bacteria as vehicles for systemic delivery of agents
JP2013500015A (ja) 2009-07-24 2013-01-07 イミューン デザイン コーポレイション シンドビスウイルスエンベロープ糖タンパク質により偽型化したレンチウイルスベクター
CA2769822C (en) 2009-08-13 2019-02-19 The Johns Hopkins University Methods of modulating immune function
CN104826106B (zh) 2009-09-30 2019-01-11 斯隆凯特林防癌纪念中心 用于治疗癌症的组合免疫疗法
EP2531216B1 (en) 2010-02-04 2019-03-27 The Trustees Of The University Of Pennsylvania Icos critically regulates the expansion and function of inflammatory human th17 cells
KR20130049775A (ko) 2010-03-12 2013-05-14 애브비 바이오테라퓨틱스 인크. Ｃｔｌａ４ 단백질 및 이의 용도
KR101860963B1 (ko) 2010-04-23 2018-05-24 제넨테크, 인크. 이종다량체 단백질의 생산
US9029315B2 (en) 2010-11-11 2015-05-12 The University Of Hong Kong Soluble PD-1 variants, fusion constructs, and uses thereof
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
JP5972915B2 (ja) 2011-03-16 2016-08-17 アムジエン・インコーポレーテツド Ｆｃ変異体
US9044420B2 (en) 2011-04-08 2015-06-02 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
KR20140029446A (ko) 2011-04-15 2014-03-10 컴퓨젠 엘티디. 면역 관련 장애 및 암의 치료를 위한 폴리펩티드 및 폴리뉴클레오티드, 및 이들의 용도
WO2012149364A1 (en) 2011-04-28 2012-11-01 Diamond Don J Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy
CN102836441B (zh) 2011-06-24 2019-06-11 台北荣民总医院 于感染性与恶性疾病的治疗中提升免疫反应的方法
MY180616A (en) 2011-06-30 2020-12-03 Genzyme Corp Inhibitors of t-cell activation
CA2836855C (en) * 2011-06-30 2020-07-14 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
US8956619B2 (en) 2011-10-25 2015-02-17 University Of Maryland, Baltimore County Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
WO2013130683A2 (en) 2012-02-27 2013-09-06 Amunix Operating Inc. Xten conjugate compositions and methods of making same
CN104583231B (zh) 2012-03-30 2021-02-26 免疫设计公司 具有对表达dc-sign的细胞改善的转导效率的慢病毒载体粒子
WO2013156054A1 (en) 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
AU2013260172B2 (en) 2012-05-11 2017-11-23 Medimmune Limited CTLA-4 variants
US20150322119A1 (en) * 2012-12-03 2015-11-12 Bristol-Myers Squibb Company Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
TW201439115A (zh) 2012-12-04 2014-10-16 Oncomed Pharm Inc 使用結合劑之免疫治療
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
US20160017041A1 (en) 2013-03-15 2016-01-21 Biogen Ma Inc. Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies
RU2015146419A (ru) 2013-04-23 2017-05-26 Зе Юниверсити Корт Оф Зе Юниверсити Оф Абердин Выделение терапевтических доменов vnar, специфичных по отношению к мишени icosl
WO2014198002A1 (en) 2013-06-14 2014-12-18 Ottawa Hospital Research Institute A bacterium producing an interferon binding protein and uses thereof
US20160271218A1 (en) 2013-06-27 2016-09-22 Mor Research Applications Ltd. Soluble ctla-4 molecules and derivatives thereof for treatment of minimal change disease
GB201311475D0 (en) 2013-06-27 2013-08-14 Alligator Bioscience Ab Polypeptides
US10238700B2 (en) 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
EP3094647A1 (en) 2014-01-15 2016-11-23 F. Hoffmann-La Roche AG Fc-region variants with modified fcrn- and maintained protein a-binding properties
WO2015120363A1 (en) 2014-02-10 2015-08-13 Emory University Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer
JP6775422B2 (ja) 2014-03-28 2020-10-28 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ３８及びｃｄ３に結合する二重特異性抗体
AU2015289773A1 (en) 2014-07-15 2017-02-02 Immune Design Corp. Prime-boost regimens with a TLR4 agonist adjuvant and a lentiviral vector
JP6895374B2 (ja) 2014-07-16 2021-06-30 トランジェーヌＴｒａｎｓｇｅｎｅ 免疫チェックポイントモジュレーターの発現用腫瘍溶解性ウイルス
DK3177640T3 (da) 2014-08-08 2020-08-10 Univ Leland Stanford Junior Pd-1-midler med høj affinitet og anvendelsesfremgangsmåder
SG10201901735XA (en) 2014-09-03 2019-03-28 Bavarian Nordic As Recombinant modified vaccinia virus ankara (mva) filovirus vaccine
US20160145344A1 (en) 2014-10-20 2016-05-26 University Of Southern California Murine and human innate lymphoid cells and lung inflammation
JP2018501302A (ja) 2014-11-06 2018-01-18 チルドレンズ リサーチ インスティテュート、チルドレンズ ナショナル メディカル センター 癌及び自己免疫疾患のための免疫療法剤
EP3020816A1 (en) 2014-11-11 2016-05-18 University College Cork Bacterial mediated gene therapy
WO2016118577A1 (en) 2015-01-22 2016-07-28 Medimmune, Llc Thymosin-beta-four fusion proteins
US10953045B2 (en) 2015-04-02 2021-03-23 Cancure Limited Agents and compositions for eliciting an immune response
WO2016164428A1 (en) 2015-04-06 2016-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor-based antagonists of the programmed cell death 1 (pd-1) pathway
KR20240046641A (ko) 2015-04-17 2024-04-09 알파인 이뮨 사이언시즈, 인코포레이티드 조율가능한 친화성을 갖는 면역조절 단백질
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
KR102761886B1 (ko) 2015-07-30 2025-02-06 마크로제닉스, 인크. Pd-1-결합 분자 및 그것의 사용 방법
WO2017023779A1 (en) 2015-07-31 2017-02-09 Tarveda Therapeutics, Inc. Compositions and methods for immuno-oncology therapies
EP3328363A4 (en) 2015-07-31 2019-08-21 Tarveda Therapeutics, Inc. COMPOSITIONS AND METHOD FOR IMMUNOMODULATION
KR20180054713A (ko) 2015-09-14 2018-05-24 알파인 이뮨 사이언시즈, 인코포레이티드 조율가능한 변종 면역글로불린 수퍼패밀리 도메인 및 유전자 조작된 세포 치료법
MX2018003936A (es) 2015-10-02 2018-07-06 Symphogen As Anticuerpos anti proteina de muerte celular programada 1 (pd-1) y composiciones.
US11684656B2 (en) 2015-11-04 2023-06-27 Taipei Veterans General Hospital Combination therapy for malignant diseases
MA44082A (fr) 2015-12-14 2018-10-24 Macrogenics Inc Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation
MA43551A (fr) 2016-04-15 2018-11-07 Alpine Immune Sciences Inc Protéines immunomodulatrices à variants du ligand icos et leurs utilisations
KR102764225B1 (ko) 2016-04-15 2025-02-07 알파인 이뮨 사이언시즈, 인코포레이티드 Cd80 변이체 면역조절 단백질 및 그의 용도
US11339201B2 (en) 2016-05-18 2022-05-24 Albert Einstein College Of Medicine Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
CN110088127A (zh) 2016-07-28 2019-08-02 高山免疫科学股份有限公司 Cd155变体免疫调节蛋白及其用途
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
EP3872180A1 (en) 2016-10-20 2021-09-01 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
EP3596116B1 (en) 2017-03-16 2023-09-06 Alpine Immune Sciences, Inc. Pd-l1 variant immunomodulatory proteins and uses thereof
US20200283500A1 (en) 2017-10-18 2020-09-10 Alpine Immune Sciences, Inc. Variant icos ligand immunomodulatory proteins and related compositions and methods
EP3735417A1 (en) 2018-01-03 2020-11-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
EP3955953A1 (en) 2019-04-17 2022-02-23 Alpine Immune Sciences, Inc. Methods and uses of variant icos ligand (icosl) fusion proteins

Also Published As

Publication number Publication date
IL313289A (en) 2024-08-01
KR20230051602A (ko) 2023-04-18
WO2017181148A3 (en) 2018-02-01
SG11201808457PA (en) 2018-10-30
AU2017250358A1 (en) 2018-10-18
MX2022009923A (es) 2022-09-09
KR102536850B1 (ko) 2023-05-26
NZ746741A (en) 2023-12-22
KR20190005879A (ko) 2019-01-16
KR102824067B1 (ko) 2025-06-23
BR112018070934A2 (pt) 2019-02-26
AU2017250358B2 (en) 2023-06-01
US20210188995A1 (en) 2021-06-24
JP2024138024A (ja) 2024-10-07
IL262365A (en) 2018-11-29
NZ787246A (en) 2025-12-19
CN110088126A (zh) 2019-08-02
US10882914B2 (en) 2021-01-05
IL262365B2 (en) 2024-11-01
CA3019199A1 (en) 2017-10-19
EP3442999A2 (en) 2019-02-20
JP2019514361A (ja) 2019-06-06
IL262365B1 (en) 2024-07-01
JP2022064959A (ja) 2022-04-26
KR20230051601A (ko) 2023-04-18
US12110339B2 (en) 2024-10-08
WO2017181148A2 (en) 2017-10-19
JP7058609B2 (ja) 2022-04-22
JP7623967B2 (ja) 2025-01-29
KR20250095754A (ko) 2025-06-26
MX2018012472A (es) 2019-08-12
AU2023202718A1 (en) 2023-05-18
NZ787243A (en) 2025-12-19
NZ787244A (en) 2025-12-19
US20170320959A1 (en) 2017-11-09
US20240409660A1 (en) 2024-12-12

Similar Documents

Publication Publication Date Title
MA43551A (fr) Protéines immunomodulatrices à variants du ligand icos et leurs utilisations
MA43552A (fr) Protéines immunomodulatrices à variants de cd80 et leurs utilisations
EP3523328A4 (en) VARIANT ACTRIIB PROTEINS AND USES THEREOF
EP3810182A4 (en) Neoantigens and uses thereof
MA50618A (fr) Polyrhérapies et leurs utilisations
MA42622A (fr) Agents de liaison à tigit et leurs utilisations
EP3344275A4 (en) PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF
EP3471727A4 (en) CXCR4 INHIBITORS AND USES THEREOF
MA41460A (fr) Agents de liaison à la tnfrsf et leurs utilisations
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
EP3472129A4 (en) CXCR4 INHIBITORS AND USES THEREOF
EP3426288A4 (en) ANTI-PACAP ANTIBODIES AND USES THEREOF
EP3328895A4 (en) ANTI-PD-1 ANTIBODIES AND USES THEREOF
EP3294318A4 (en) PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF
EP3334706A4 (en) PILLARARES AND USES THEREOF
MA46704A (fr) Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
EP2991665A4 (en) STACKED AND GRAFTED POLYPEPTIDES AND USES THEREOF
EP3283516A4 (en) ANTI-PACAP ANTIBODIES AND USES THEREOF
MA50404A (fr) Protéines immunomodulatrices à variants de ligand de icos variant, compositions et méthodes associées
EP3383904A4 (en) CTLA-4 ANTIBODIES AND USES THEREOF
EP3478516A4 (en) MULTIPLE STRUCTURES AND USE THEREOF
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
EP3325010A4 (en) ANTIBODIES AGAINST COZY FACTOR XIA AND USES THEREOF
EP3538261A4 (en) PEROWSKIT CATALYSTS AND USES THEREOF
DK3535397T3 (da) Alfa-v-beta-6-integrin-ligander og anvendelser deraf